Alida Biosciences

Alida Bio is a biotechnology startup that operates in the field of gene regulation. The company focuses on understanding the complex relationships in gene regulation, specifically the role of epigenetic markers, which include modifications of DNA, RNA, and histone proteins. These markers play a crucial role in controlling how the genetic code is used in health and disease. Alida Bio's technology is unique in that it can detect and locate many epigenetic markers at once, unlike current methods that can only detect one at a time.

The company's work has significant implications for drug development, particularly in the field of cancer treatment. Alida Bio is exploring new drug targets, including RNA modification writers, erasers, and readers, which are becoming important cancer drug targets. The company is also involved in therapeutic RNA editing, which is gaining traction as a potentially safer alternative to DNA editing methods like CRISPR.

Alida Bio's technology is also valuable for basic and clinical research. By identifying and locating RNA modifications, researchers can gain a better understanding of systems biology and disease mechanisms. This could lead to the development of new diagnostics and treatment regimes.

The company's business model involves providing assays, or tests, that can study RNA modifications. These assays can save researchers time and reduce variability in their experiments. Alida Bio also offers a proprietary analysis pipeline that can interpret complex genomics data, accessible via cloud or as a desktop application.

Alida Bio's revenue comes from selling their assays and analysis software to researchers and pharmaceutical companies. They also offer partnerships for early access to their technology, providing tailored support from their experienced team.

Keywords: Biotechnology, Gene Regulation, Epigenetic Markers, Drug Development, Cancer Treatment, RNA Editing, Clinical Research, Assays, Genomics Data Analysis, Partnerships.